ABCL
$11.38
+$0.42 (3.81%)+3.81%
ClosedLoading chart...
IndexN/A
Market Cap3.48B
Enterprise Value1.04B
Income$-0.05B
Sales$0.00B
EmployeesN/A
P/E-21.07
P/S13.60
P/B1.06
P/C-5.87
EV/EBITDA-6.97
EV/SalesN/A
EPS (ttm)-0.54
EarningsN/A
Gross Margin61.64%
Oper. Margin-288.98%
Profit Margin-194.88%
Volume12.31M
Shs Outstand0.31B
Change3.74%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $28.83M | $38.02M | $485.42M | $375.20M | $233.16M | $11.61M | $8.83M |
| Cost of Revenue | $0.00 | $0.00 | $66.44M | $45.52M | $27.14M | $0.00 | $5.80M |
| Gross Profit | $28.83M | $38.02M | $418.99M | $329.69M | $206.01M | $11.61M | $3.03M |
| Gross Margin | 100.00% | 100.00% | 86.31% | 87.87% | 88.36% | 100.00% | 34.29% |
| Operating Expenses | $343.60M | $275.23M | $202.48M | $125.27M | $49.98M | $15.73M | $3.78M |
| Operating Income | $-314.77M | $-237.21M | $216.51M | $204.41M | $156.03M | $-4.12M | $-753.00K |
| Operating Margin | -1091.69% | -623.82% | 44.60% | 54.48% | 66.92% | -35.45% | -8.53% |
| Net Income | $-162.86M | $-146.40M | $158.52M | $153.46M | $118.92M | $-2.21M | $309.00K |
| Net Margin | -564.83% | -385.00% | 32.66% | 40.90% | 51.00% | -19.04% | 3.50% |
| EPS (Basic) | $-0.55 | $-0.51 | $0.56 | $0.56 | $0.32 | $-0.01 | $0.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | $23.49M | $21.49M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $304.47M | $335.78M | $307.63M | $292.84M | $175.03M | $13.24M | $9.88M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.06B | $1.15B | $1.23B | $1.03B | $830.51M | $10.25M | $11.61M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.06B | $1.15B | $1.23B | $1.03B | $830.51M | $10.25M | $11.61M |
| Total Liabilities & Stockholders Equity | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B | $23.49M | $21.49M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-162.86M | $-146.40M | $158.52M | $153.46M | $118.92M | $-2.21M | $309.00K |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-108.56M | $-43.88M | $277.36M | $244.58M | $22.69M | $2.69M | $3.56M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Prelude Cuts Q2 Losses and Costs 13%The Motley Fool Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsightGlobeNewswire Inc. Down 57%, Is AbCellera Biologics a Buy on the Dip?The Motley Fool AbCellera Biologics (ABCL) Q1 2024 Earnings Call TranscriptThe Motley Fool AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out forZacks Investment Research AbCellera Biologics (ABCL) Q4 2023 Earnings Call TranscriptThe Motley Fool
Show 12 more stories
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research Techne (TECH) Q2 Earnings and Revenues Lag EstimatesZacks Investment Research 4 Magnificent Healthcare Stocks to Buy in 2024 and BeyondThe Motley Fool 3 Growth Stocks That Could Go Parabolic in 2024The Motley Fool Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?Zacks Investment Research AbCellera Biologics (ABCL) Q3 2023 Earnings Call TranscriptThe Motley Fool Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to DeclineZacks Investment Research New Strong Buy Stocks for October 26thZacks Investment Research Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term ProspectsBenzinga My Newborn Son's Roth IRA And The Fabulous Wonders Of CompoundingSeeking Alpha Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Discover more
You may be interested in